The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation

This study is a prospective, multicenter, open-label, randomized non-inferiority trial comparing intravenous ibandronate and zoledronic acid as sequential therapy after denosumab discontinuation in postmenopausal women with osteoporosis. This trial primarily targets patients with short-term denosumab exposure (less than three years) and is conducted as a preliminary investigation. The findings are expected to provide foundational evidence to inform the design of future studies assessing sequential therapies following longer-term denosumab treatment.

NCT Number	NCT07406685
Lead Sponsor	National Taiwan University Hospital Collaborators: National Taiwan University
Conditions	Postmenopausal Osteoporosis, Postmenopausal Osteopenia, Primary Osteoporosis, Osteoporosis
Enrollment	52 participants
Start Date	2026-03-17
Primary Completion	2030-03-17 (estimated)
Study Completion	2030-09-17 (estimated)
Updated on ClinicalTrials.gov	2026-02-12